Inventor · disambiguated record
Xin Ye
Also filed as: YE XIN · YE XIN KATHERINE · YE XIN-SHAN
14 granted patents·16 pending applications·89 citations·filing 1999–2024
90Inventor score
Files withJIANGSU HENGRUI MEDICINE CO10JIANGSU HENGRUI PHARMACEUTICALS CO LTD4ARBUTUS BIOPHARMA CORP3GENENTECH INC2GENEVANT SCIENCES GMBH2
Top patents by PatentIndex Score
30 records- 0194US10905743B2Interleukin 15 protein complexJIANGSU HENGRUI MEDICINE CO·Filed 2015·Granted Feb 2, 2021·9 cites·10 claims
- 0292US12043833B2Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2022·Granted Jul 23, 2024·1 cites·18 claims
- 0392US10344090B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jul 9, 2019·15 cites·27 claims
- 0491US11717559B2Interleukin 15 protein complex and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Aug 8, 2023·2 cites·15 claims
- 0591US11427823B2Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2018·Granted Aug 30, 2022·5 cites·16 claims
- 0690US10206980B2IL-15 heterodimeric protein and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Feb 19, 2019·20 cites·19 claims
- 0786US11365255B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2019·Granted Jun 21, 2022·2 cites·12 claims
- 0886US7019131B2Programmable one-pot oligosaccharide synthesisSCRIPPS RESEARCH INST·Filed 2003·Granted Mar 28, 2006·20 cites·12 claims
- 0982US2025179496A1Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2024·Application pending·0 cites
- 1067US2025215042A1Mannose-targeted compositionsGENEVANT SCIENCES GMBH·Filed 2023·Application pending·0 cites
- 1166US2024269136A1Egfr inhibitor and perk activator in combination therapy and their use for treating cancerGENENTECH INC·Filed 2023·Application pending·0 cites
- 1265US10899837B2B7-H3 antibody, antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jan 26, 2021·0 cites·17 claims
- 1364US2025376519A1Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1462US2025057968A1Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibodyJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1561US11680100B2B7-H3 antibody, antigen-binding fragment thereof and medical use thereofHANSOH SHANGHAI HEALTHTECH CO LTD·Filed 2020·Granted Jun 20, 2023·0 cites·17 claims
- 1661US6538117B1Programmable one-pot oligosaccharide synthesisSCRIPPS RESEARCH INST·Filed 1999·Granted Mar 25, 2003·15 cites·3 claims
- 1760US2024352132A1Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1859US12227583B2Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical useJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Feb 18, 2025·0 cites·17 claims
- 1958US2024392020A1Antigen-binding moleculeJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2058US2023123270A1Spatial-dependent analysis of biological material from intact tissue samplesGENENTECH INC·Filed 2022·Application pending·0 cites
- 2155US2022387600A1Conjugates and methods for treating liver fibrosisGENEVANT SCIENCES GMBH·Filed 2020·Application pending·0 cites
- 2254US2025017903A1Use of edaravone in treatment of autism spectrum disorderSUZHOU AUZONE BIOLOGICAL TECH CO LTD·Filed 2022·Application pending·0 cites
- 2352US2023257472A1Anti-cd70 antibody and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Application pending·0 cites
- 2451US10793643B2PCSK9 antibody, antigen-binding fragment thereof, and medical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 6, 2020·0 cites·24 claims
- 2550US12428482B2Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Sep 30, 2025·0 cites·19 claims
- 2647US2023012428A1Bifunctional fusion protein and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 2747US2022275100A1Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical useJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2846US2004170989A1Cellular gene targets for controlling cell growthFiled 2003·Application pending·0 cites
- 2944US2005136485A1Iterative one-pot oligosaccharide synthesisFiled 2004·Application pending·0 cites
- 3039US2020270365A1Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xin Ye files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →